Research Paper Volume 14, Issue 15 pp 6358—6376
Clinical outcomes and potential therapies prediction of subgroups based on a ferroptosis-related long non-coding RNA signature for gastric cancer
Figure 7. Drug prediction and immunotherapy prediction uncover potential clinical treatment associated with FRLSG. (A) Venn plot for summarizing available compounds in CTRP, GDSC and PRISM projects. (B) Scatter diagram demonstrating candidate drugs with potential therapeutic effect for (B) high-FRLSG patients and (C) low-FRLSG patients (D) Prediction of the response to anti-PD-1 therapy and anti-CTLA4 therapy for the high- and low-FRLSG GC patients.